Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
Ching‐Yao Yang(National Taiwan University Hospital), Chong‐Jen Yu(National Taiwan University Hospital), Kang‐Yi Su(National Taiwan University), Jin‐Yuan Shih(National Taiwan University Hospital), Chen‐Tu Wu(National Taiwan University Hospital), Jih‐Hsiang Lee(National Cancer Institute), James Chih‐Hsin Yang(National Taiwan University Hospital), Bin-Chi Liao(National Taiwan University Hospital), Chia‐Chi Hsu(National Taiwan University Hospital), Chao‐Chi Ho(National Taiwan University Hospital), Yih‐Leong Chang(National Taiwan University), Wei‐Hsun Hsu(Royal Prince Alfred Hospital), Yinan Liu(The First Hospital of Changsha), Kuan‐Yu Chen(Ming Chi University of Technology), Tzu‐Hsiu Tsai(National Taiwan University Hospital), Wei‐Yu Liao(National Taiwan University Hospital), Chia‐Chi Lin(National Taipei University of Technology), Chia‐Lin Hsu(National Taiwan University Hospital)
Cited by 25
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k